Home › Companies › INTRA-CELLULAR THERAPIES INC. › 2023-2024
Compiled from SEC Form N-PX filings and INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 14, 2024: 4 items on INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed June 18, 2024: 2 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore INTRA-CELLULAR THERAPIES INC. in the interactive database Compare manager voting policies
These tallies are INTRA-CELLULAR THERAPIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Joel S. Marcus | 54,287,176 | -- | -- | 38,126,412 | 3,812,995 | 59% | Not verified | — |
| 2. Approval of the Amended 2018 Plan, based on the following results | 85,384,880 | 2,956,962 | 4,071,746 | -- | 3,812,995 | 97% | Not verified | — |
| 3. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 88,688,988 | 3,237,807 | 4,299,788 | -- | 0 | 96% | Approved | — |
| 4. On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement | 80,788,125 | 7,537,868 | 4,087,595 | -- | 3,812,995 | 91% | Approved | — |
Source: INTRA-CELLULAR THERAPIES INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.
Each item below shows how the 357 asset managers that disclosed a INTRA-CELLULAR THERAPIES INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
59% Majority: yes · of votes cast
Description as filed by funds: To elect one director to serve a three-year term expiring in 2027: Joel S. Marcus
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Elect Director: Joel S. Marcus”): 54,287,176 for, 38,126,412 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 59% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 958,550 | 0 | 0 | 9,534,538 | Mixed |
| Fidelity | 10,125,019 | 0 | 0 | 61,058 | For |
| BlackRock | 0 | 0 | 0 | 4,545,940 | Withhold |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 1,749,302 | Withhold |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,099,670 | Withhold |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 990,389 | Withhold |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 825,243 | Withhold |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 570,007 | Withhold |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 419,947 | Withhold |
| Principal | 179,428 | 0 | 0 | 228,516 | Mixed |
| American Century | 390,414 | 0 | 0 | 0 | For |
| Brighthouse | 113,542 | 0 | 0 | 252,428 | Mixed |
| Equitable | 1,200 | 0 | 0 | 357,520 | Withhold |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 267,081 | Withhold |
| Jackson National | 62,334 | 0 | 0 | 200,406 | Mixed |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 109 managers: 22,165,607 for, 22,869,687 withheld. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 193,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 2 managers: 536,606 for.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“2. Approval of the Amended 2018 Plan, based on the following results”): 85,384,880 for, 2,956,962 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of INTRA-CELLULAR THERAPIES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (2 managers, 19,752 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 1,749,302 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 300,618 | 107,326 | 0 | 0 | Mixed |
| American Century | 0 | 390,414 | 0 | 0 | Against |
| Brighthouse | 348,434 | 0 | 17,536 | 0 | For |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 262,740 | 0 | 0 | 0 | For |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 108 managers: 44,251,963 for, 746,292 against, 1 withheld, 17,536 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 193,000 | 0 | 0 | 0 | For |
| MITCHELL CAPITAL MANAGEMENT CO | 300 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 536,906 for.
Combines 10 wordings of this item as funds reported it.
91% Approved · of votes cast
Description as filed by funds: To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“4. On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement”): 80,788,125 for, 7,537,868 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement was approved, based on the following votes:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 0 | 1,749,302 | 0 | 0 | Against |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 407,944 | 0 | 0 | 0 | For |
| American Century | 0 | 390,414 | 0 | 0 | Against |
| Brighthouse | 113,542 | 234,892 | 17,536 | 0 | Mixed |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| Hartford | 273,382 | 34,347 | 0 | 0 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 0 | 262,740 | 0 | 0 | Against |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 109 managers: 42,089,931 for, 2,927,826 against, 1 withheld, 17,536 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 12,629,610 | 0 | 0 | 0 | For |
| BlackRock | 3,418,211 | 19,868 | 0 | 0 | For |
| WASATCH ADVISORS LP | 2,780,281 | 20,192 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,204,635 | 0 | 0 | 0 | For |
| State Street | 1,996,115 | 28,267 | 0 | 0 | For |
| Invesco | 0 | 2,015,113 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 1,687,918 | 161 | 0 | 0 | For |
| T. Rowe Price | 1,651,072 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,525,991 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,465,042 | 0 | 0 | 0 | For |
| JPMorgan | 1,425,782 | 0 | 0 | 0 | For |
| Wellington | 1,423,209 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,372,114 | 0 | 0 | 0 | For |
| MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | 1,291,551 | 0 | 0 | 0 | For |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,280,768 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 1,206,614 | 3,989 | 0 | 0 | For |
| Charles Schwab | 1,122,610 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 1,072,173 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,051,507 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 924,590 | 0 | 0 | 0 | For |
| Northern Trust | 840,634 | 5,131 | 0 | 0 | For |
| Nuveen | 829,732 | 0 | 0 | 0 | For |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 0 | 625,114 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 625,000 | 0 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 523,218 | 0 | 0 | 0 | For |
Institutional-manager reports, all 274 managers: 54,572,312 for, 5,764,498 against, 62 not voted, 2 unknown. Showing the 25 largest; see all in the interactive database.
Combines 5 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“3. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 88,688,988 for, 3,237,807 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, based on the following results:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,493,088 | 0 | 0 | 0 | For |
| Fidelity | 10,186,077 | 0 | 0 | 0 | For |
| BlackRock | 4,545,940 | 0 | 0 | 0 | For |
| WASATCH FUNDS TRUST | 2,135,726 | 0 | 0 | 0 | For |
| Invesco | 1,749,302 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,258,648 | 0 | 0 | 0 | For |
| Charles Schwab | 1,099,670 | 0 | 0 | 0 | For |
| Legg Mason | 1,006,717 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 990,389 | 0 | 0 | 0 | For |
| JPMorgan | 892,794 | 0 | 0 | 0 | For |
| TIAA | 825,243 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 694,609 | 0 | 0 | 0 | For |
| First Trust | 639,766 | 0 | 0 | 0 | For |
| AllianceBernstein | 570,007 | 0 | 0 | 0 | For |
| Lord Abbett | 463,762 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 419,947 | 0 | 0 | 0 | For |
| Principal | 407,944 | 0 | 0 | 0 | For |
| American Century | 390,414 | 0 | 0 | 0 | For |
| Brighthouse | 348,434 | 0 | 17,536 | 0 | For |
| Equitable | 358,720 | 0 | 0 | 0 | For |
| Hartford | 307,729 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 267,081 | 0 | 0 | 0 | For |
| Jackson National | 262,740 | 0 | 0 | 0 | For |
| AMG FUNDS | 253,068 | 0 | 0 | 0 | For |
| GENERAL AMERICAN INVESTORS CO INC | 244,036 | 0 | 0 | 0 | For |
Fund voting reports, all 110 managers: 44,915,327 for, 102,680 against, 1 withheld, 17,536 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TimesSquare Capital Management, LLC | 343,606 | 0 | 0 | 0 | For |
| Altium Capital Management LP | 193,000 | 0 | 0 | 0 | For |
| ZIMMERMANN INVESTMENT MANAGEMENT & PLANNING LLC | 83 | 0 | 0 | 0 | For |
Institutional-manager reports, all 3 managers: 536,689 for.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 10,493,088 |
| 2 | Fidelity | 10,186,077 |
| 3 | BlackRock | 4,545,940 |
| 4 | WASATCH FUNDS TRUST | 2,135,726 |
| 5 | Invesco | 1,749,302 |
| 6 | T. Rowe Price | 1,258,648 |
| 7 | Charles Schwab | 1,099,670 |
| 8 | Legg Mason | 1,006,717 |
| 9 | Delaware/Macquarie | 990,389 |
| 10 | JPMorgan | 892,794 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Fidelity | 12,629,610 |
| 2 | BlackRock | 3,438,079 |
| 3 | WASATCH ADVISORS LP | 2,800,473 |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2,204,635 |
| 5 | State Street | 2,024,382 |
| 6 | Invesco | 2,015,113 |
| 7 | Clearbridge Investments, LLC | 1,688,079 |
| 8 | T. Rowe Price | 1,651,072 |
| 9 | Deep Track Capital, LP | 1,525,991 |
| 10 | AllianceBernstein | 1,465,042 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to INTRA-CELLULAR THERAPIES INC. for the 2023-2024 season, so there is no denominator to divide by.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At INTRA-CELLULAR THERAPIES INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 357 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 2,058 separate fund positions. On the most widely held item on that ballot — To approve by an advisory vote the compensation of the Company's named executive officers, as… — INTRA-CELLULAR THERAPIES INC.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: INTRA-CELLULAR THERAPIES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.
INTRA-CELLULAR THERAPIES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.
Download data (CSV): ballot items · votes by manager · column guide.